Cognition Thought Leadership
Conversations: Fireside Video Chats
The new “Conversations” video series will feature virtual fireside chats with neuroscience experts who will discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions. Please use the form at the bottom of our webpage you submit your comments or feedback.
Please note, our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.
Featuring: | |
Anthony Caggiano, M.D., Ph.D. Cognition Therapeutics |
Chief Medical Officer |
C. Gustavo De Moraes, M.D., Ph.D. (moderator) Columbia University and Ora (CRO) |
Associate Professor of Clinical Ophthalmology Chief Medical Officer |
Jeffrey S. Heier, M.D. Ophthalmic Consultants of Boston |
Director of the Vitreoretinal Service & Retina Research |
Peter K. Kaiser, M.D. Cleveland Clinic Lerner College of Medicine |
Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology |


Episode 5: Exploring the Effects of CT1812 on Alzheimer’s Disease Processes: Proteomics and Pathways of Neurodegeneration
Featuring: | |
Mary Hamby, Ph.D. Cognition Therapeutics |
Vice President of Research |
Charlotte Teunissen, Ph.D. (moderator) Amsterdam University Medical Center |
Professor of Clinical Neurochemistry |
Nicholas Seyfried, Ph.D. Emory University School of Medicine |
Professor of Biochemistry and Neurology Director of the Emory Integrated Proteomics Core |
Henrik Zetterberg, MD, Ph.D. Gothenburg University |
Professor of Neuroscience Group Leader of the UK Dementia Research Institute |

Index: | |
0:00 | Introduction |
01:53 | Utility of Proteomic Analysis in Alzheimer’s |
03:20 | Review of Proteomics Findings from AD/PD 2023 |
08:36 | Key Learnings |
Episode 4: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies
Featuring: | |
Anthony Caggiano, M.D., Ph.D. Cognition Therapeutics |
Chief Medical Officer and Head of Research & Development |
Brendan Kelley, M.D. (moderator) University of Texas SW |
Vice Chair for Clinical Operations at the Peter O’Donnell Jr. Brain Institute and a Professor in the Department of Neurology |
Sarah B. Berman, M.D., Ph.D. University of Pittsburgh |
Associate Professor in the Departments of Neurology and Clinical & Translational Science and Director of DLB Programs at the ARDC |
James Leverenz, M.D. Cleveland Clinic |
Director of the Lou Ruvo Center for Brain Health |
David Shprecher, D.O. Banner Sun Health Research Institute |
Movement Disorder Director and a Clinical Associate Professor at the University of Arizona |

Index: | |
0:00 | Introduction |
01:09 | Part I: The Intersection of Alzheimer’s and DLB |
07:23 | Biomarker Tests for DLB |
09:11 | Part II: Practical insights for community HCPs |
09:40 | Frequency of missed or delayed diagnosis of DLB |
12:48 | Facets of patient-reported memory loss |
19:46 | Nuances of psychological symptoms |
24:23 | Cognitive Fluctuations |
Episode 3: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia
Featuring: | |
Lisa Ricciardi Cognition Therapeutics |
President & Chief Executive Officer |
Norma Loeb Lewy Body Dementia Resource Center |
Founder and Executive Director |
Mary Lou Falcone M.L. FALCONE, Public Relations |
Board member, LBD Resource Center Author of “I Didn’t See It Coming, a Memoir of Love, Loss, and Lewy Body Dementia” |

Index: | |
0:00 | Introduction |
2:30 | Key symptoms and signs of Lewy body dementia |
9:44 | The importance of an accurate diagnosis |
13:30 | Preparing for a doctor visit |
15:30 | Resources, support and caring for the caregiver |
Episode 2: Building on Amyloid Lowering: Key Insights from Recent Data and Prospects for Complementary Therapeutic Approaches
Featuring: | |
Anthony Caggiano, M.D., Ph.D. Cognition Therapeutics |
Chief Medical Officer and Head of R&D |
Christopher H. van Dyck, M.D. Yale University School of Medicine |
Professor of Psychiatry, Neurology, and Neuroscience; Director of the Division of Aging and Geriatric Psychiatry; Director of the Alzheimer’s Disease Research Center |
Anton P. Porsteinsson, M.D. University of Rochester School of Medicine and Dentistry |
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine; and Director of the Alzheimer’s Disease Care, Research and Education Program (AD-CARE) |

Index: | |
0:00 | Introduction |
1:47 | Reactions to lecanemab results |
3:48 | Impact of targeting plaque |
6:46 | Potentially complementary strategies |
11:24 | Future of Alzheimer’s therapies |
13:40 | Conclusion |
Featuring: | |
Anthony Caggiano, M.D., Ph.D. Cognition Therapeutics |
Chief Medical Officer and Head of R&D |
James Galvin, M.D., MPH University of Miami Miller School of Medicine |
Director of the Comprehensive Center for Brain Health Principal Investigator of the SHIMMER Study |

Index: | |
0:00 | Introduction |
1:09 | What is DLB |
3:13 | Diagnostic Challenges |
6:38 | Potential Treatment Strategy |
7:48 | Designing a Clinical Trial |
8:42 | Conclusion |
Leadership Editorials
BioTuesdays
By Lisa Ricciardi
February 21, 2023
Investment Reports by Newsweek
By Lisa Ricciardi
February 21, 2023
Drug Discovery and Development Magazine
By Anthony Caggiano
January 4, 2023
MedCity News
By Lisa Ricciardi
October 1, 2022